We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 01, 2021

First-Line Nivolumab + Ipilimumab in Advanced NSCLC

Journal of Thoracic Oncology

 

Additional Info

Journal of Thoracic Oncology
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
J Thorac Oncol 2021 Oct 11;[EPub Ahead of Print], LG Paz-Ares, SS Ramalingam, TE Ciuleanu, JS Lee, L Urban, RB Caro, K Park, H Sakai, Y Ohe, M Nishio, C Audigier-Valette, JA Burgers, A Pluzanski, R Sangha, C Gallardo, M Takeda, H Linardou, L Lupinacci, KH Lee, C Caserta, M Provencio, E Carcereny, GA Otterson, M Schenker, B Zurawski, A Alexandru, A Vergnenegre, J Raimbourg, K Feeney, SW Kim, H Borghaei, KJ O'Byrne, MD Hellmann, A Memaj, FE Nathan, J Bushong, P Tran, JR Brahmer, M Reck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading